EF Hutton Maintains Buy on Annovis Bio, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Annovis Bio (NYSE:ANVS) and maintained a price target of $21.
October 15, 2024 | 4:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Annovis Bio and maintained a price target of $21, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a maintained price target of $21 by EF Hutton suggests a positive outlook for Annovis Bio. This can lead to increased investor confidence and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100